Clavis Pharma Starts ELACYT(TM) Phase II Study In Haematology

Clavis Pharma (OSE: CLAVIS) announced that it has started recruiting patients to the phase II part of its clinical phase I/II study with ELACYT(TM), within haematological cancers. The phase II part commences after the successful completion of phase I, which demonstrated a good safety profile, as well as clinical activity. The phase II part will evaluate the efficacy and safety of ELACYT in patients with late stage acute myeloid leukaemia (AML).

More: continued here

Filed under: Blood on April 4th, 2008